| 15.13 0.29 (1.95%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.03 | 1-year : | 23.39 |
| Resists | First : | 17.14 | Second : | 20.03 |
| Pivot price | 15.81 |
|||
| Supports | First : | 13.72 | Second : | 11.6 |
| MAs | MA(5) : | 15.38 |
MA(20) : | 15.51  |
| MA(100) : | 11.67 |
MA(250) : | 9.13 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 26.5 |
D(3) : | 39.3 |
| RSI | RSI(14): 52.3 |
|||
| 52-week | High : | 17.14 | Low : | 3.72 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ COGT ] has closed above bottom band by 18.9%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.28 - 15.38 | 15.38 - 15.47 |
| Low: | 14.67 - 14.8 | 14.8 - 14.92 |
| Close: | 14.93 - 15.13 | 15.13 - 15.32 |
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Fri, 24 Oct 2025
Cogent Biosciences Announces Promising Preclinical Data for KRAS(ON) Inhibitor at 2025 AACR-NCI-EORTC Conference - Quiver Quantitative
Fri, 24 Oct 2025
Cogent Bio (NASDAQ: COGT) says CGT1815 shows superior efficacy vs RMC-6236 in KRAS models - Stock Titan
Wed, 22 Oct 2025
Cogent Biosciences (NASDAQ:COGT) Stock Price Down 9.3% - Here's Why - MarketBeat
Tue, 21 Oct 2025
Cogent Biosciences (NASDAQ:COGT) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Tue, 21 Oct 2025
Cogent Biosciences (COGT) Price Target Increased by JPMorgan - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 140 (M) |
| Shares Float | 103 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 105.9 (%) |
| Shares Short | 17,010 (K) |
| Shares Short P.Month | 13,070 (K) |
| EPS | -2.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -53.2 % |
| Return on Equity (ttm) | -107.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -234 (M) |
| Levered Free Cash Flow | -126 (M) |
| PE Ratio | -7.28 |
| PEG Ratio | 0 |
| Price to Book value | 36.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|